

PATENT ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT								
NATURE OF CONVEYANCE:	ASSIGNMENT								
CONVEYING PARTY DATA									
<table border="1"> <thead> <tr> <th>Name</th> <th>Execution Date</th> </tr> </thead> <tbody> <tr> <td>Samedy Ouk</td> <td>12/18/2012</td> </tr> <tr> <td>Jean-Michel Vernier</td> <td>12/18/2012</td> </tr> <tr> <td>Esmir Gunic</td> <td>12/18/2012</td> </tr> </tbody> </table>		Name	Execution Date	Samedy Ouk	12/18/2012	Jean-Michel Vernier	12/18/2012	Esmir Gunic	12/18/2012
Name	Execution Date								
Samedy Ouk	12/18/2012								
Jean-Michel Vernier	12/18/2012								
Esmir Gunic	12/18/2012								
RECEIVING PARTY DATA									
Name:	Ardea Biosciences, Inc.								
Street Address:	4939 Directors Place								
City:	San Diego								
State/Country:	CALIFORNIA								
Postal Code:	92121								
PROPERTY NUMBERS Total: 1									
<table border="1"> <thead> <tr> <th>Property Type</th> <th>Number</th> </tr> </thead> <tbody> <tr> <td>Application Number:</td> <td>13703891</td> </tr> </tbody> </table>		Property Type	Number	Application Number:	13703891				
Property Type	Number								
Application Number:	13703891								
CORRESPONDENCE DATA									
Fax Number:	6504936811								
<i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i>									
Phone:	858-350-2300								
Email:	smmartin@wsgr.com								
Correspondent Name:	Ingo H. Hardt, Ph.D., Esq.								
Address Line 1:	650 Page Mill Road								
Address Line 4:	Palo Alto, CALIFORNIA 94304								
ATTORNEY DOCKET NUMBER:	18545-770.831								
NAME OF SUBMITTER:	Sarah Rollins								
Total Attachments: 1 source=18545-770-831-Assignment#page1.tif									

CH \$40.00 13703891

PATENT ASSIGNMENT

Docket Number 18545-770.831

WHEREAS, the undersigned:

- | | | |
|---|---|---|
| 1. OUK, Samedy
10790 Dabney Drive, Apt. 2
San Diego, CA 92121 | 2. VERNIER, Jean-Michel
5150 Sea Mist
San Diego, CA 92121 | 3. GUNIC, Esmir
8952 Capcano Road
San Diego, CA 92129 |
|---|---|---|

(hereinafter "Inventor(s)"), have invented certain new and useful improvements in

PHENYLTHIOACETATE COMPOUNDS, COMPOSITIONS AND METHODS OF USE

for which Application No. 13/703,891, a U.S. National Phase of PCT/US11/40586 filed on June 15, 2011 in the U.S. Receiving Office of the Patent Cooperation Treaty; (hereinafter "Application(s)").

WHEREAS, Ardea Biosciences, Inc., a corporation of the State OR Commonwealth of Delaware, having a place of business at 4939 Directors Place, San Diego, CA, 92121, (hereinafter "Assignee"), is desirous of acquiring the entire right, title and interest in and to said Application(s) and the inventions disclosed therein, and in and to all embodiments of the inventions, heretofore conceived, made or discovered, whether jointly or severally, by said Inventor(s) (hereinafter collectively referred to as "Inventions"), and in and to any and all patents, inventor's certificates and other forms of protection (hereinafter "Patent(s)") thereon granted in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty.

NOW, THEREFORE, in consideration of good and valuable consideration acknowledged by said Inventor(s) to have been received in full from said Assignee:

1. Said Inventor(s) do hereby sell, assign, transfer and convey unto said Assignee the entire right, title and interest (a) in and to said Inventions and said Applications, including the right to claim priority to said Inventions and said Applications; (b) in and to all rights to all United States and corresponding non-United States patent applications and Patent(s), including those filed under the Paris Convention for the Protection of Industrial Property, The Patent Cooperation Treaty or otherwise; (c) in and to any and all applications filed and any and all Patent(s) granted on said Inventions in the United States, in any foreign country, or under any international convention, agreement, protocol, or treaty, including each and every application filed and any and all Patent(s) granted on any application which is a divisional, substitution, continuation, or continuation-in-part of any of said Application(s); and (d) in and to each and every reissue, reexamination, or extensions of any of said Patent(s).

2. Said Inventor(s) hereby covenant and agree to cooperate with said Assignee to enable said Assignee to enjoy to the fullest extent the right, title and interest herein conveyed in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty. Such cooperation by said Inventor(s) shall include prompt production of pertinent facts and documents, giving of testimony, execution of petitions, oaths, specifications, declarations or other papers, and other assistance all to the extent deemed necessary or desirable by said Assignee (a) for perfecting in said Assignee the right, title and interest herein conveyed; (b) for prosecuting any applications covering said Inventions; (c) for filing and prosecuting substitute, divisional, continuing or additional applications covering said Inventions; (d) for filing and prosecuting applications for reissuance of any said Patent(s); (e) for interference or other priority proceedings involving said Inventions; and (f) for legal proceedings involving said Inventions and any applications therefor and any Patent(s) granted thereon, including without limitation reissues and reexaminations, opposition proceedings, cancellation proceedings, priority contests, public use proceedings, infringement actions and court actions; provided, however, that the expense incurred by said Inventor(s) in providing such cooperation shall be paid for by said Assignee.

3. The terms and covenants of this assignment shall inure to the benefit of said Assignee, its successors, assigns and other legal representatives, and shall be binding upon said Inventor(s), their respective heirs, legal representatives and assigns.


4. Said Inventor(s) hereby warrant and represent that they have not entered and will not enter into any assignment, contract, or understanding in conflict herewith.

5. Said Inventor(s) hereby request that any Patent(s) issuing in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty, be issued in the name of the Assignee, or its successors and assigns, for the sole use of said Assignee, its successors, legal representatives and assigns.


6. This instrument will be interpreted and construed in accordance with the laws of the State of California, without regard to conflict of law principles. If any provision of this instrument is found to be illegal or unenforceable, the other provisions shall remain effective and enforceable to the greatest extent permitted by law. This instrument may be executed in counterparts, each of which is deemed an original, but all of which together constitute one and the same agreement.

IN WITNESS WHEREOF, said Inventor(s) have executed and delivered this instrument to said Assignee as of the dates written below:

Date: Dec 18, 2012 
 Samedy OUK

Date: 12-18-12 
 Jean-Michel VERNIER

Date: 12/19/2012 
 Esmir GUNIC

RECEIVED AND AGREED TO BY ASSIGNEE: Ardea Biosciences, Inc.
 Date: i Dec 2012 By: 
 Name: Barry D. Quart
 Title: President, CEO and Director